NextCure Delays 2 Clinical Trials Due to Coronavirus
On Monday, clinical-stage biopharmaceutical company NextCure (NASDAQ: NXTC) announced that it would be delaying the start of upcoming phases of clinical trials for two immuno-oncology drug candidates, NC318 and NC410.
"The COVID-19 pandemic has put significant strain on our clinical trial sites, and has raised concerns around monitoring patient safety," the company wrote in a business update. "We, like others in our industry, are working closely with our clinical partners and taking the necessary steps to adjust our protocols and timelines as required during this challenging time."
Image source: Getty Images.
Source Fool.com
